Skip to main content

SRPT

Stock
Health Care
Biotechnology

Performance overview

SRPT Price
Price Chart

Forward-looking statistics

Beta
0.70
Risk
46.78%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$11.7B

Fundamentals

Enterprise value$2.5B
Revenue$2.2B
Revenue per employee—
Profit margin-11.12%
Debt to equity118.73

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.64
Dividend per share—
Revenue per share$23.28
Avg trading volume (30 day)$105M
Avg trading volume (10 day)$92M
Put-call ratio—

Macro factor sensitivity

Growth+0.9
Credit+5.1
Liquidity+0.2
Inflation-0.3
Commodities-1.1
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio1.53
Price to sales0.77
P/E Ratio1.53
Enterprise Value to Revenue1.13
Price to book1.51

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

Zacks Investment Research (July 21, 2025)
BMO's Kostas Biliouris: It will be challenging for the FDA to force a market withdrawal for Sarepta

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on Sarepta after the company declined the FDA's request to halt shipments of its gene therapy.

CNBC Television (July 21, 2025)
Sarepta Therapeutics: Why Is SRPT Stock Crashing?

Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.

Forbes (July 21, 2025)
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

The ground shook for Sarepta Therapeutics, Inc. SRPT last week as the U.S. Food and Drug Administration (FDA), alarmed by a third patient death tied to its gene therapy platform, pulled a rare move: requesting a voluntary halt to Elevidys shipments. The company's response?

Benzinga (July 21, 2025)
Sarepta shares plunge 30% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.

CNBC (July 18, 2025)
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.'s SRPT Elevidys treatment and evaluating the need for further regulatory action.

Benzinga (June 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free